Silencing Triglycerides: The Clinical Impact of Plozasiran and apoC-III Inhibition in Severe Hypertriglyceridemia

Severe hypertriglyceridemia (sHTG) is a critical metabolic disorder that substantially elevates the risk of atherosclerotic vascular disease and acute pancreatitis. Despite its clinical significance, many conventional triglyceride-lowering therapies often fail to adequately reduce triglyceride levels or prevent these life-threatening complications. This unmet need has spurred interest in targeting regulatory proteins involved in triglyceride metabolism, such as apolipoprotein C3 (apoC-III), a key inhibitor of lipoprotein lipase activity that promotes triglyceride-rich lipoprotein (TRL) accumulation. Plozasiran, an investigational small interfering RNA (siRNA) therapy, has emerged as a breakthrough in sHTG management by selectively degrading hepatic APOC3 mRNA. Indeed, clinical trials demonstrate this drug’s robust efficacy in reducing triglyceride levels, concomitant with reduced non-HDL cholesterol and apolipoprotein B—key markers of cardiovascular risk. Notably, the Phase III PALISADE trial in familial chylomicronemia syndrome patients revealed plozasiran’s potential to mitigate acute pancreatitis risk by normalizing triglyceride levels with a favorable safety profile. Current guidelines emphasize a multimodal approach to sHTG, combining dietary restriction of fats and simple carbohydrates with pharmacotherapy. However, plozasiran’s prolonged dosing interval and mechanism-based action position it as a transformative option, particularly for patients refractory to existing treatments. While long-term cardiovascular outcome data remain pending, its ability to durably modulate APOC3 expression offers new hope for breaking the cycle of dyslipidemia-driven organ damage. As research progresses, this therapy may redefine standards of care for high-risk populations, bridging a critical gap in preventive cardiology and pancreatology.